Novo Nordisk to Pay $2 Billion for New Weight Loss Drug
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company.
1don MSN
The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...
Canned soup can be a nutritious and convenient way to support your weight loss efforts. Lentil and chicken-vegetable are ...
Research reveals nuts actually enhance weight loss efforts despite their calories, offering metabolic benefits that improve ...
For weight loss to be effective, we must consider the diverse factors contributing to weight gain, which vary from person to ...
While talking to PEOPLE, Kathy Bates revealed how getting 'really healthy' following her 100-lb. weight loss has directly ...
Legendary actor Kathy Bates has run the gamut throughout her acting career, with CBS’ Matlock as her most recent challenge.
Verywell Health on MSN1d
Do Weight Loss Gummies Really Help You Lose Weight? Here's What Science SaysWeight loss gummies claim to burn fat, suppress hunger, and boost your metabolism to help with weight loss, but these ...
Amy Schumer’s experience with Mounjaro has been vastly different from when she tried an alternative weight-loss medication ...
Research suggests men and women may need different breakfast compositions for weight loss success. Find 7 balanced meal ideas ...
If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...
Los Angeles Dodgers shortstop Mookie Betts' status for Opening Day remains uncertain as he continues to deal with the illness ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback